Ligand Pharmaceuticals LGND Derivative Assets, Non-Current
Derivative Assets, Non-Current at other companies
Other financials
Where this comes from
Reported directly by Ligand Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:DerivativeAssetsNoncurrent.
The official record: Ligand Pharmaceuticals’s 10-Q, filed May 8, 2026, on SEC EDGAR. View the filing →
Ask your AI about Ligand Pharmaceuticals's derivative assets, non-current.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Ligand Pharmaceuticals's derivative assets, non-current?
- Ligand Pharmaceuticals (LGND) reported derivative assets, non-current of $13.53M in Q1 2026.
- How has Ligand Pharmaceuticals's derivative assets, non-current changed year-over-year?
- Ligand Pharmaceuticals's derivative assets, non-current decreased by 25.0% year-over-year, from $18.03M to $13.53M.
- What is the long-term trend for Ligand Pharmaceuticals's derivative assets, non-current?
- Over 2 years (2023 to 2025), Ligand Pharmaceuticals's derivative assets, non-current has grown at a 110.4% compound annual growth rate (CAGR), from $3.53M to $15.63M.
- What does derivative assets, non-current mean?
- This represents the fair value of derivative financial instruments held by the company that are expected to be settled or realized after one year. These assets typically arise from hedging activities or specific financial contracts designed to manage market risks. Tracking this provides insight into the company's long-term financial risk management and exposure to market volatility.